Navigation Links
Gene therapy to lower blood pressure just enough

A newly developed virus that introduces a blood pressure-lowering gene into cells and enables that gene to maintain blood pressure at healthy levels for four months promises to take gene therapy for the disorder a step closer to reality, said researchers at Baylor College of Medicine in a report released online in the Proceedings of the National Academy of Sciences.

"High blood pressure is one of the leading causes of death and disability in adults worldwide," said Dr. Bert O'Malley, chair of the BCM department of molecular and cellular biology. "A therapy that could control blood pressure could have important benefits for individuals and for the health of the world's population as well."

The gene in question -- atrial natriuretic peptide or ANP -- promises to control blood pressure through a variety of effects on key areas involved in the problem of hypertension, including the relaxation of smooth muscle cells in blood vessels, increasing the vessels' diameters, and reducing the manner in which the vessels react to agents that can constrict those vessels. ANP also improves the manner in which the kidney eliminates sodium or salt from the body and inhibits other systems, such as the sympathetic nervous system, believed linked to development of high blood pressure.

"This makes ANP an attractive agent for use in treating blood pressure," said O'Malley. "However, its use is limited by the fact that it has such short-lived activity in the blood system."

Its activity is halved 30 seconds after it enters the blood stream.

Gene therapy can make cells generate more ANP. In previous studies, however, this kind of gene reduced blood pressure to dangerously low levels, said O'Malley. Obviously, a method of controlling the gene and the amount of ANP a cell makes was needed.

The special viral vector developed by O'Malley and his colleagues combines a special kind of adenovirus altered so it does not produce disease connected to a gene regulatory system turned on by the drug mifepristone.

Using this vector, O'Malley and his colleagues were able to introduce the ANP gene into the cells of mice. Then tiny doses of drug turned on the regulatory system, which controlled the amount of ANP made so that blood pressure remained at healthy levels for 125 days - 74 days longer than in any previous gene therapy study. Other studies indicate that the therapy could reduce the heart-weight/body-weight ratio. For this reason it has promise in reducing some of the organ damage that occurs as a result of high blood pressure.

One question that remains is whether the body will accept repeated injections of the viral vector or whether its immune system eventually react against it, said O'Malley.


Source:Baylor College of Medicine

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:

(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology: